EP2866830A4 - Anti-cxcl9-, anti-cxcl10-, anti-cxcl11-, anti-cxcl13-, anti-cxcr3- und anti-cxcr5-wirkstoffe zur hemmung von entzündungen - Google Patents

Anti-cxcl9-, anti-cxcl10-, anti-cxcl11-, anti-cxcl13-, anti-cxcr3- und anti-cxcr5-wirkstoffe zur hemmung von entzündungen

Info

Publication number
EP2866830A4
EP2866830A4 EP12880044.8A EP12880044A EP2866830A4 EP 2866830 A4 EP2866830 A4 EP 2866830A4 EP 12880044 A EP12880044 A EP 12880044A EP 2866830 A4 EP2866830 A4 EP 2866830A4
Authority
EP
European Patent Office
Prior art keywords
cxcl11
cxcl13
cxcl9
cxcr5
cxcl10
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12880044.8A
Other languages
English (en)
French (fr)
Other versions
EP2866830A1 (de
Inventor
James W Lillard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JYANT TECHNOLOGIES
Original Assignee
JYANT TECHNOLOGIES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JYANT TECHNOLOGIES filed Critical JYANT TECHNOLOGIES
Publication of EP2866830A1 publication Critical patent/EP2866830A1/de
Publication of EP2866830A4 publication Critical patent/EP2866830A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
EP12880044.8A 2012-06-27 2012-06-27 Anti-cxcl9-, anti-cxcl10-, anti-cxcl11-, anti-cxcl13-, anti-cxcr3- und anti-cxcr5-wirkstoffe zur hemmung von entzündungen Withdrawn EP2866830A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/044464 WO2014003742A1 (en) 2012-06-27 2012-06-27 Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation

Publications (2)

Publication Number Publication Date
EP2866830A1 EP2866830A1 (de) 2015-05-06
EP2866830A4 true EP2866830A4 (de) 2015-12-09

Family

ID=49783685

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12880044.8A Withdrawn EP2866830A4 (de) 2012-06-27 2012-06-27 Anti-cxcl9-, anti-cxcl10-, anti-cxcl11-, anti-cxcl13-, anti-cxcr3- und anti-cxcr5-wirkstoffe zur hemmung von entzündungen

Country Status (5)

Country Link
EP (1) EP2866830A4 (de)
JP (1) JP2015524793A (de)
CN (2) CN112807427A (de)
HK (1) HK1212628A1 (de)
WO (1) WO2014003742A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2717661T3 (es) * 2014-04-08 2019-06-24 Fraunhofer Ges Forschung Terapia de combinación para el tratamiento de las enfermedades autoinmunes
CN105039319A (zh) * 2015-06-22 2015-11-11 浙江理工大学 用于预测乳腺癌新辅助化疗疗效的生物标记物和荧光定量免疫pcr试剂盒
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CN107236023B (zh) * 2017-05-12 2021-05-07 苏州创澜生物科技有限公司 一种用于检测结核感染的抗原组合物及其应用
JP6994726B2 (ja) * 2017-11-24 2022-02-04 ソウル大学校産学協力団 グラフェンナノ構造体を含む抗炎症用組成物
CN110511912B (zh) * 2018-08-30 2024-03-22 浙江煦顼技术有限公司 免疫细胞的功能调节
CN109777784B (zh) * 2019-02-22 2021-12-31 上海尚泰生物技术有限公司 一种增强向肿瘤部位迁移的嵌合抗原受体载体构建方法与应用
CN114341178B (zh) * 2019-07-02 2024-05-07 机敏医药股份有限公司 Ccl14的抗体和检测
JP2022544169A (ja) 2019-08-07 2022-10-17 エディフィス・ヘルス・インコーポレイテッド 心血管疾患の処置および予防
EP3960861A1 (de) * 2020-08-31 2022-03-02 Rheinische Friedrich-Wilhelms-Universität Bonn Auf cxcl9-abzielende aptamere
CN114432502B (zh) * 2021-12-31 2023-02-03 中山大学附属第八医院（深圳福田） 一种负载op3-4多肽、抗cxcl9抗体的水凝胶及其制备方法与应用
EP4499836A2 (de) * 2022-03-30 2025-02-05 Flagship Pioneering Innovations V. Inc. Cxcl-modulierende zusammensetzungen und verfahren
CN121431851A (zh) * 2024-07-19 2026-01-30 北京量觉科技有限责任公司 免疫相关不良反应标志物及试剂盒
CN119405785A (zh) * 2025-01-07 2025-02-11 首都医科大学附属北京儿童医院 Cxcl11作为抗病毒药物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2012082494A2 (en) * 2010-12-14 2012-06-21 Morehouse School Of Medicine The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE360689T1 (de) * 1996-09-10 2007-05-15 Kocher Theodor Inst Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
PE20090993A1 (es) * 2007-08-29 2009-07-08 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
EP2611832B1 (de) * 2010-09-02 2017-11-29 Vaccinex, Inc. Anti-cxcl13-antikörper und verfahren zu ihrer verwendung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2012082494A2 (en) * 2010-12-14 2012-06-21 Morehouse School Of Medicine The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
ANTHONY T. CORCORAN ET AL: "Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens", WORLD JOURNAL OF UROLOGY., vol. 31, no. 1, 24 March 2012 (2012-03-24), DE, pages 241 - 246, XP055246159, ISSN: 0724-4983, DOI: 10.1007/s00345-012-0852-y *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2008 (2008-04-01), HARDI ROBERT ET AL: "A phase 1 open-label, single-dose, dose-escalation study of Mdx-1100, a high-affinity, neutralizing, fully human Igg1 kappa anti-CXCL10 (Ip10) monoclonal antibody, in ulcerative colitis", Database accession no. PREV200800413054 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2005 (2005-03-01), GLABINSKI ANDRZEJ ET AL: "Modulation of brain immune-mediated inflammation with anti-chemokine antibodies", XP002747239, Database accession no. PREV200510320434 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2005 (2005-03-01), SINGH UDAI P ET AL: "Colitis in IL-10-/- mice is mediated in part by CXCL10 production by CD4+T cells, neutrophils, and NK cells as well as CXCR3+ dendritic cells", Database accession no. PREV200510321754 *
EGESTEN ARNE ET AL: "The proinflammatory CXC-chemokines GRO-[alpha]/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids", INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, SPRINGER VERLAG, BERLIN, DE, vol. 22, no. 12, 1 December 2007 (2007-12-01), pages 1421 - 1427, XP036332319, ISSN: 0179-1958, [retrieved on 20071201], DOI: 10.1007/S00384-007-0370-3 *
FASEB JOURNAL, vol. 19, no. 4, Suppl. S, Part 1, March 2005 (2005-03-01), EXPERIMENTAL BIOLOGY 2005 MEETING/35TH INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES; SAN DIEGO, CA, USA; MARCH 31 -APRIL 06, 2005, pages A7 - A8, ISSN: 0892-6638 *
FASEB JOURNAL, vol. 19, no. 5, Suppl. S, Part 2, March 2005 (2005-03-01), EXPERIMENTAL BIOLOGY 2005 MEETING/35TH INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES; SAN DIEGO, CA, USA; MARCH 31 -APRIL 06, 2005, pages A1443, ISSN: 0892-6638 *
FLIER J ET AL: "Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation", JOURNAL OF PATHOLOGY, JOHN WILEY & SONS LTD, GB, vol. 194, no. 4, 1 August 2001 (2001-08-01), pages 398 - 405, XP002432876, ISSN: 0022-3417, DOI: 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S *
GASTROENTEROLOGY, vol. 134, no. 4, Suppl. 1, April 2008 (2008-04-01), DIGESTIVE DISEASE WEEK MEETING/109TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; SAN DIEGO, CA, USA; MAY 17 -22, 2008, pages A99 - A100, ISSN: 0016-5085 *
HOSOMI S ET AL: "S1705 Increased Numbers of Immature Plasma Cells in Peripheral Blood Overexpress Chemokine Receptor Cxcr3 and Cxcr4 in Ulcerative Colitis", GASTROENTEROLOGY, W.B. SAUNDERS CO, US, vol. 136, no. 5, 1 May 2009 (2009-05-01), pages A - 253, XP026111698, ISSN: 0016-5085, [retrieved on 20090501], DOI: 10.1016/S0016-5085(09)61151-3 *
JENNY L. HARDISON ET AL.: "The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi", INFECTION AND IMMUNITY, vol. 74, no. 1, January 2006 (2006-01-01), pages 125 - 134, XP002747240 *
LACHER ET AL: "Association of a CXCL9 polymorphism with pediatric Crohn's disease", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 363, no. 3, 6 October 2007 (2007-10-06), pages 701 - 707, XP022288917, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2007.09.020 *
OGAWA T ET AL: "CXCR3 Binding Chemokine and TNFSF14 Over Expression in Bladder Urothelium of Patients With Ulcerative Interstitial Cystitis", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 183, no. 3, 1 March 2010 (2010-03-01), pages 1206 - 1212, XP026938446, ISSN: 0022-5347, [retrieved on 20100301], DOI: 10.1016/J.JURO.2009.11.007 *
RUSCHPLER PETER ET AL: "High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis", ARTHRITIS RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 5, no. 5, 26 June 2003 (2003-06-26), pages R241 - R252, XP021011812, ISSN: 1465-9905, DOI: 10.1186/AR783 *
S. HOSOMI ET AL: "Increased numbers of immature plasma cells in peripheral blood specifically overexpress chemokine receptor CXCR3 and CXCR4 in patients with ulcerative colitis", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 163, no. 2, 19 November 2010 (2010-11-19), GB, pages 215 - 224, XP055509681, ISSN: 0009-9104, DOI: 10.1111/j.1365-2249.2010.04290.x *
See also references of WO2014003742A1 *
UDAI SINGH ET AL: "CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication", ENDOCRINE, METABOLIC & IMMUNE DISORDERS - DRUG TARGETS, vol. 7, no. 2, 1 June 2007 (2007-06-01), NL, pages 111 - 123, XP055360654, ISSN: 1871-5303, DOI: 10.2174/187153007780832109 *

Also Published As

Publication number Publication date
WO2014003742A1 (en) 2014-01-03
HK1212628A1 (zh) 2016-06-17
CN112807427A (zh) 2021-05-18
JP2015524793A (ja) 2015-08-27
EP2866830A1 (de) 2015-05-06
CN104870013A (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
EP2675469A4 (de) Zusammensetzungen, vorrichtungen und verwendungsverfahren dafür zur behandlung von krebs
IL238400A (en) Triazulophyrazines as brd4 inhibitors for use in cancer treatment
PT2920149T (pt) Compostos de 3-aminocicloalquil como inibidores de ror-gama-t e utilizações dos mesmos
ZA201402475B (en) Self-adhesive lavatory treatment compositions
EP2678018A4 (de) Kombination von kinasehemmern und verwendungen dafür
IL253911A0 (en) Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
PL3329919T3 (pl) Inhibitory ACC i ich zastosowania
IL237475A0 (en) Pyrlotriazinone derivatives as pi3k inhibitors
EP2830654B8 (de) Verfahren und zusammensetzungen zur behandlung von entzündungen
IL238177A0 (en) Methods and preparations for the treatment of cancer
IL233111A0 (en) Preparations for the treatment of inflammation
IL228719A0 (en) parp inhibitors for the treatment of cipn
EP2897689A4 (de) Zusammensetzungen und verfahren zur behandlung von alopezie
HUE046572T2 (hu) TFPI inhibitorok és alkalmazási eljárások
IL236138A (en) Dipluoro-hexahydro-cyclophenoxazinyls and diplooro-hexahydro-benzooxazinyls as bace inhibitors1
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
EP2768331A4 (de) Schutzvorrichtungen, komponenten dafür und verfahren zu ihrer verwendung
SI2617412T1 (sl) Sestavek za topično zdravljenje
GB201100651D0 (en) Treatment of inflammation
GB201218486D0 (en) Novel selective bromodomains inhibitors for the treatment of inflammation,cancer and viral infections
GB201218281D0 (en) Novel selective bromodomains inhibitors for the treatment of inflammation, cancer and viral infections
GB201218282D0 (en) Novel selective bromodomains inhibitors for the treatment of inflammation, cancer and viral infections
HK1189818A (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101ALI20151023BHEP

Ipc: A61P 29/00 20060101ALI20151023BHEP

Ipc: A61K 39/395 20060101AFI20151023BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151106

17Q First examination report despatched

Effective date: 20170406

18D Application deemed to be withdrawn

Effective date: 20170817

18RA Request filed for re-establishment of rights before grant

Effective date: 20180626

D18D Application deemed to be withdrawn (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

R18D Application deemed to be withdrawn (corrected)

Effective date: 20200113